GLP-1 and Longevity

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after a meal. It tells your brain you're full, slows how fast your stomach empties, and helps control insulin.

GLP-1 agonists are lab-made copies of that signal. They stick around in the body much longer than the real thing. The main drugs:

• Semaglutide, sold as Ozempic (diabetes) or Wegovy (obesity). Weekly injection.
• Tirzepatide, sold in the EU as Mounjaro for type 2 diabetes and obesity. In the US, the obesity brand is Zepbound (not marketed in the EU). It hits two hunger receptors instead of one (GLP-1 plus GIP).
• Liraglutide, the older version. Daily injection.

These drugs were built for type 2 diabetes. But the weight loss in trials was so large (10 to 22 percent of body weight in phase-3 studies) that regulators also cleared them for obesity.

The longevity question is a separate one. Do they help people live longer or healthier, beyond the weight loss itself?

This guide is not medical advice. GLP-1 agonists are prescription drugs with real risks. Talk to your doctor.

Short answer: no. Losing weight and living longer are related, but they are not the same thing.

Long-running observational studies show obesity (BMI over 30) is linked to several years of lost life expectancy. So reversing obesity should, in theory, win some of those years back. The reality is more complicated.

Here is what the data say:

• The method matters a lot. Bariatric surgery cut all-cause mortality by roughly 20 to 30 percent over 10-plus years (the SOS cohort, NEJM 2007). Lifestyle-only weight loss did not reduce heart events in people with type 2 diabetes. That was Look AHEAD, which stopped early for futility in 2012. So the benefit doesn't come from the weight loss in isolation.
• In people with a normal BMI, there is no evidence yet that GLP-1 extends life. Every trial has been run in people with obesity or diabetes.
• Weight loss costs you lean body mass, usually about 25 to 40 percent of the weight you drop. Lean body mass (what a DEXA scan reports) includes skeletal muscle plus water, glycogen, bone, and organ tissue, so the pure muscle share is smaller. But the skeletal-muscle loss on GLP-1s is real. Losing it risks worse mobility and metabolic health later, unless you add strength training and enough protein.

So the real longevity question becomes: are there benefits beyond the weight loss itself? Early studies point to a few believable mechanisms. The data are still young.

Three large randomised trials drive the current longevity debate.

SELECT (NEJM 2023) enrolled 17,604 people with obesity and existing heart disease, but no diabetes. They took semaglutide 2.4 mg weekly, mean exposure 33 months, mean follow-up about 40 months. The primary endpoint hit: a 20 percent drop in major heart-and-blood-vessel events (3P-MACE = CV death, heart attack, or stroke; HR 0.80, 95 percent CI 0.72 to 0.90). Semaglutide also showed a nominal reduction in all-cause mortality (HR 0.81, 95 percent CI 0.71 to 0.93). But an earlier endpoint in SELECT's pre-specified testing sequence did not cross its threshold, so the mortality result counts as hypothesis-generating, not statistically confirmed. It's still the strongest evidence so far for a heart-protective, and possibly lifespan-related, effect.

STEP-HFpEF (2023) tested semaglutide in people with heart failure (the kind where the heart pumps but stays stiff) plus obesity. Symptoms and exercise capacity improved.

FLOW (2024) tested semaglutide in people with type 2 diabetes and chronic kidney disease. The result: a 24 percent drop in major kidney and heart-and-blood-vessel events.

Then there is the liver. MASH stands for metabolic dysfunction-associated steatohepatitis, a serious fatty-liver disease. ESSENCE Part 1 results supported the FDA approval of Wegovy (semaglutide 2.4 mg) for noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3) on 15 August 2025. The EMA CHMP adopted a positive opinion on 29 January 2026 recommending conditional marketing authorisation under the EU brand name Kayshild, and the European Commission granted that authorisation on 26 March 2026. Kayshild is now authorised EU-wide for noncirrhotic MASH with F2-F3 fibrosis. The conditional authorisation requires further evidence from the ongoing ESSENCE Part 2 trial, with a 240-week clinical-event read-out expected 2029. Tirzepatide is not approved for MASH in any jurisdiction as of May 2026, despite social-media claims to the contrary. The Phase 2 SYNERGY-NASH trial (NEJM 2024) is the published evidence to date.

Next-generation candidates worth watching. Eli Lilly's orforglipron, branded Foundayo in the US, was approved by the FDA on 1 April 2026 for adults with obesity or overweight plus weight-related medical problems, under the FDA's CNPV (Commissioner's National Priority Voucher) pilot pathway (NDA 220934, the fastest NME approval since 2002 at about 50 days from filing). It's the first oral non-peptide GLP-1 receptor agonist and can be taken any time of day, with no food or water restrictions. The Phase 3 read-outs: ACHIEVE-1 (T2D, 1.3 to 1.6% A1C reduction at the highest dose), ATTAIN-1 (obesity, about 12.4% weight loss at 72 weeks in the highest-dose completer analysis, published in NEJM), and ATTAIN-2 (obesity plus T2D). EMA marketing authorisation status is not publicly confirmed as of May 2026. Verify on the EMA register.

Retatrutide, also Eli Lilly, is a triple GLP-1/GIP/glucagon agonist. The first positive Phase 3 read-out (TRIUMPH-4, in obesity plus knee osteoarthritis) was published in December 2025, with up to 28.7% mean weight loss at the highest dose and significant pain reduction. More Phase 3 read-outs are expected through 2026. Retatrutide is not FDA- or EMA-approved as of May 2026, and Swissmedic warned on 26 August 2025 about falsified "retatrutide injection kits" sold on social media. The substance stays research-only.

What we still don't know:

• Direct lifespan data over 10-plus years
• The effect in people without risk factors (healthy-weight BMI)
• Long-term safety across multiple decades
• Whether the benefits stick around after you stop (early hint: most of the weight comes back within 1 to 2 years)

SELECT-LIFE, a non-interventional observational follow-up of SELECT participants, is ongoing and may give us longer-term outcomes data. It is not a randomised mortality arm, so hard lifespan answers will still need a dedicated trial.

GLP-1 agonists are not harmless supplements. The risks come in two tiers.

Common (10 to 40 percent of users):

• Nausea, especially in the first weeks
• Diarrhoea or constipation
• Vomiting
• Loss of appetite (that's the point, but it can tip into eating too little)

Less common but serious:

• Pancreatitis (inflamed pancreas). Get medical help right away.
• Gallbladder problems, including a higher risk of gallstones and cholecystitis.
• Gastroparesis (stomach empties too slowly). The ASA recommends discussing a pre-op pause with the prescriber. Its 2023 consensus suggested pausing weekly GLP-1 agonists for one week, and daily agents on the day of the procedure, before anaesthesia or deep sedation. The October 2024 multi-society update (ASA, AGA, ASMBS, ISPCO, SAGES) softened that universal rule into a risk-stratified, shared-decision approach (for example, gastric ultrasound or dietary changes) rather than automatic discontinuation. Either way, tell your anaesthetist what you take. Pulmonary aspiration from retained gastric contents has been reported.
• Acute kidney injury from dehydration, if nausea or vomiting stops you drinking enough fluid.
• Medullary thyroid carcinoma (MTC) and MEN-2: warning per EMA SmPC §4.4 (not §4.3 contraindications) and FDA boxed warning. A personal or family history of MTC or Multiple Endocrine Neoplasia type 2 is treated as a hard stop in clinical practice. The label is based on rodent thyroid C-cell tumour findings. Human risk is uncertain, but prescribing is generally avoided.
• Non-arteritic anterior ischaemic optic neuropathy (NAION), a type of sudden vision loss. The signal was first reported with semaglutide in JAMA Ophthalmology 2024 (HR 4.28, 95 percent CI 1.62 to 11.29, single-centre cohort). A larger OHDSI multi-database replication (JAMA Ophthalmology, April 2025, 14 databases, 37.1M adults with T2D) reported a meta-analysis IRR of about 1.32 (95% CI 1.14 to 1.54), described in the abstract as "a modest increase in the risk of NAION.. smaller than that previously reported." A separate Danish-Norwegian cohort (Simonsen et al., 2025, senior author Anton Pottegård) reported a pooled HR of 2.81 (95% CI 1.67 to 4.75). After the PRAC conclusion of 5 June 2025, the semaglutide SmPCs were updated through autumn 2025 to list NAION as a very rare (under 1 in 10,000) adverse reaction. Seek urgent ophthalmology review for sudden painless vision loss.
• Diabetic retinopathy worsening in patients who already have retinopathy (the SUSTAIN-6 signal).
• Muscle and bone loss if you don't plan around it.

Mental health: Reports of mood changes and, in a few cases, suicidal thoughts are still being reviewed by regulators. The EMA PRAC concluded in April 2024 that no cause-and-effect link was proven, but monitoring continues.

Cost and supply (Germany): Wegovy and Mounjaro for obesity are excluded from GKV reimbursement under §34 Abs. 1 Satz 7 SGB V (Lifestyle-Arzneimittel, AM-RL Anlage II). They are always self-pay in Germany, roughly €170 to 500 per month depending on drug and dose (Wegovy maintenance dose about €277/month after Novo Nordisk's price cut in April 2025; Mounjaro €206 to 489/month after Lilly's price increase in February 2025). Ozempic (semaglutide, up to 2 mg) and Mounjaro for type-2 diabetes are reimbursed on the approved indication via your diabetologist or internist. Off-label prescribing of Ozempic for obesity without diabetes violates GKV rules and has drawn repeated KBV correspondence. BfArM issued warnings in 2023 to 2024 about counterfeit Ozempic circulating during shortage-driven grey-market imports. Only fill prescriptions at licensed pharmacies.

The honest picture has nuance.

If you have obesity or type 2 diabetes: the data are now solid enough that GLP-1 agonists count among the most effective tools we have, with direct heart and kidney benefits. That decision belongs with a doctor, ideally one with endocrinology or cardiology expertise.

At a normal weight, optimising for longevity: this is speculation, not science. Off-label low-dose use gets talked about in longevity circles (especially in the US), but the evidence is basically not there. The known risks (muscle loss, gut side effects, rare serious problems) don't disappear just because the proven benefit isn't there yet.

Non-negotiable companions to any GLP-1 use:

• Strength training (2 to 3 times a week) to keep muscle
• Higher protein intake (1.6 to 2.0 g per kg body weight)
• Regular DEXA or InBody scans to track body composition
• Heart checkups and blood work per your doctor's plan

Qualification ladder for German readers:

• BMI ≥30 alone (obesity), OR BMI 27 to under 30 with at least one weight-related comorbidity (dysglycaemia/prediabetes/T2DM, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease) means Wegovy is indicated per the EMA SmPC. BMI ≥30 does not require a comorbidity. Statutory insurance (GKV) will not reimburse for obesity (AM-RL Anlage II Lifestyle-Arzneimittel exclusion), but a private Rezept via your Hausarzt or an Adipositas-Schwerpunktpraxis is legal and standard. Self-pay runs roughly €170 to 500 per month depending on drug and dose.
• Type 2 diabetes (any BMI) means Ozempic or Mounjaro are reimbursed by GKV on indication, via your diabetologist or internist.
• Normal BMI, seeking "longevity" means no clinical indication. Off-label prescribing for this purpose is very rare in Germany and not supported by existing trials.

Monitoring checklist:

• Baseline (before first injection): HbA1c, TSH, fasting glucose, lipid panel, lipase, eGFR, liver enzymes. Pregnancy test where relevant. Document starting weight and body composition (DEXA or InBody) if possible.
• Weeks 0 to 16 (titration): nausea is normal early. Slow the dose escalation if vomiting persists for ≥1 week. Track weight weekly.
• Quarterly ongoing: HbA1c, lipid panel, lipase, renal function. DEXA or InBody every 6 months to catch lean-mass loss.
• Reasons to contact your prescriber promptly: persistent vomiting or dehydration, lipase rising above 3× the upper limit of normal, gallbladder pain, unexplained neck swelling, pregnancy.

Muscle-protection protocol: These are points to raise with the prescribing physician, not a self-managed protocol. Minimum while on GLP-1: 3 full-body strength sessions per week at RPE 7 to 8, 2 to 3 reps in reserve. Protein 1.6 to 2.0 g per kg body weight. DEXA at baseline and 6 months. If lean-mass loss exceeds 10% over 6 months, your prescriber may consider slowing or pausing the dose.

Women's-health note: For menstruating women, GLP-1s can change cycle length and interact with oral contraceptives. Delayed gastric emptying reduces absorption. Discuss contraception with your gynaecologist. Back-up barrier methods are recommended during titration and for 4 weeks after each dose increase. There are no human pregnancy safety data, so stop at least 2 months before planned conception.

What the research actually says: a healthy body is the means, not the goal. Any tool that reverses obesity has plausible longevity potential. But thinness at any cost is not a health goal. GLP-1 with training is not the same outcome as GLP-1 without training.